Navigation Links
Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
Date:3/20/2008

tive chemotherapy. The primary endpoint was progression-free survival. The primary objective of the trial was to detect a 40% increase in median PFS or equivalently an increase of 3-year PFS from 21% to 32.8% in all patients randomized to perioperative chemotherapy, with 80% power and two-sided significance level of 5%, resulting in HR=0.71.

In this parallel-group trial, 364 patients with up to four liver metastases initially considered resectable were randomly assigned to the standard regimen arm to be treated by either surgery alone or to the experimental arm for treatment with perioperative FOLFOX4 given in six cycles for three months before and six cycles for three months after surgery 182 patients in each arm. Upon further evaluation, 11 patients in each arm were found ineligible for inclusion. In the chemotherapy arm, 159 patients were operated (87.4%) against 170 in the surgery arm (93.4%). Resection of the liver metastases was able to be performed in a similar number of patients in each arm: 152 (83.5%) patients in the surgery arm and 151 patients in the FOLFOX4 arm (83.0%). Of these, 115 patients (63%) also received post-operative chemotherapy.

About Colorectal Cancer

Metastatic colorectal cancer means that the cancer has spread to other nodes and/or organs in the body. The most frequent sites of colorectal cancer metastases are the liver and the lung. More than half of colorectal cancer patients (55%) develop liver metastases, usually within the first two years following surgery removing the primary tumor.

Colorectal cancer is a leading cause of death. Every year, about one million new cases of colorectal cancer are diagnosed worldwide. About 150,000 new cases are detected each year in the United States. According to the American Cancer Society, colorectal cancer is the third leading cause of cancer-related death in the U.S., accounting for about 10% of all cancer deaths. Over a lifetime, about 1 in 18 people develop colorectal
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
6. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
7. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
8. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
9. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014  Grammy Award-winner Bruce Hornsby ... of philanthropists, athletes, actors, and musicians during the 10 ... 19 at the Mandarin Oriental Hotel in ... will honor six individuals who embody the values of ... bestow its highest honor, the Spirit of an Active ...
(Date:10/31/2014)... Oct. 31, 2014 Mast Therapeutics, Inc. (NYSE ... results for the quarter ended September 30, 2014. ... Officer, said:  "The third quarter was productive for Mast. Consistent ... of MST-188 for sickle cell disease is on track ... now have opened 50 study sites in the U.S. ...
(Date:10/31/2014)... 2014 Imago BioSciences, Inc., a biotech ... million Series A financing led by Clarus Ventures ... team of accomplished investment and operating professionals dedicated ... round include Frazier Healthcare, Amgen Ventures, and Merck ... and Frazier Healthcare will join the company,s board ...
Breaking Medicine Technology:10th Anniversary Orthopaedic Foundation Gala Set For Success 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures 2
... Boston Scientific Corporation (NYSE: BSX ) today announced ... Johnson & Johnson, including the Palmaz-NIR suit. All ... arena. In connection with the settlement, Boston Scientific ... & Johnson. The settlement payment is within Boston ...
... MUMBAI, India, Sept. 29 Pharmaceutical Major, Lupin Ltd. announced ... 43 mg and 130 mg). Lupin acquired the product ... of the U.S. Bankruptcy Court. Antara recorded net sales ... 2008). Lupin paid $ 38.61 million for the product ...
Cached Medicine Technology:Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes 2Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes 3Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes 4Lupin Expands Branded Play 2Lupin Expands Branded Play 3
(Date:10/31/2014)... 2014 (HealthDay News) -- Access to generic hormone therapy ... stick with their drug treatment, a new study found. ... hormone receptor-positive breast cancer can reduce recurrence by up ... associate professor of epidemiology at Columbia University Medical Center ... release. "However, work by our group and ...
(Date:10/31/2014)... Alan Mozes HealthDay ... In the world of 21st-century medicine, organ transplantation is nothing ... followed by the first liver transplant in 1963 and the ... even managed the transplantation of a patient,s entire face. ... entire human eye. But if one team of U.S. scientists ...
(Date:10/31/2014)... year, people across the United States spend an estimated ... which costs $522 billion, according to new research. ... the time and wages that caregivers give up every ... daily activities. The study authors said the significant financial ... flexibility policies. "Our findings provide a new and ...
(Date:10/30/2014)... Einstein College of Medicine of Yeshiva ... their latest aging research at the Gerontological Society ... include the identification of a genotype that can ... the cellular biology of aging. GSA 2014 will ... "Einstein-Montefiore has distinguished itself in a range of ...
(Date:10/30/2014)... Professor Elly Tanaka and her research group at the ... of Excellence at the TU Dresden (CRTD) demonstrated for ... piece of spinal cord in three dimensions from mouse ... interneurons and dorsal interneurons along the dorsal/ventral axis was ... American journal " Stem Cell Reports " on ...
Breaking Medicine News(10 mins):Health News:Generic Drugs May Help Breast Cancer Patients Stick to Therapy 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 3Health News:'Informal Care' for Older Americans Tops $500B Annually, Study Finds 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2
... Residents to Eat Right, Move More and ... Milk Their Diets, ST. ... and downs of different fad diets -- which seem to go in and ... out of three Americans -- including twenty-five percent of St.,Louis residents -- remain ...
... The Blue Cross Blue Shield of Michigan,Foundation has won ... Program. The awards, given by the Council on Foundations ... awareness of foundations and corporate giving programs. The,awards will ... Council on,Foundations on Monday, May 5, 2008 in Maryland., ...
... National Academy of Sciences of the United States has ... a member of this prestigious organization of scientists and ... in recognition of his distinguished and continuing achievements in ... has had a key role in a range of ...
... Universitys Lane Center for Computational Biology have discovered ... an automated method for analyzing cell cultures and ... online in the Journal of Machine Learning Research, ... analysis of the microscopic images produced by todays ...
... aims to educate patients on best ways to get condition ... Have asthma or think you might? Then May is the ... breathing disease. , Free asthma screenings are scheduled to be ... of National Asthma and Allergy Awareness Month. The American College ...
... - LMS Medical Systems (TSX: LMZ,AMEX: LMZ), a ... safety software system for obstetrics, today announced that ... the Company,s common,shares from Amex., The decision ... to,streamline operations and control costs in order to ...
Cached Medicine News:Health News:Message to St. Louis, MO Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to St. Louis, MO Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to St. Louis, MO Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:Blue Cross Blue Shield of Michigan Foundation Wins Three National Awards for Communications Excellence from Council on Foundations 2Health News:US honor for professor Jerry Adams 2Health News:Carnegie Mellon technique accelerates biological image analysis 2Health News:Free Asthma Screenings Offered in May 2Health News:LMS to delist from Amex 2
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
Medicine Products: